@article{3021580,
    title = "Frequency and clinical characteristics of Multiple Sclerosis rebounds after withdrawal of Fingolimod",
    author = "Evangelopoulos, M.E. and Miclea, A. and Schrewe, L. and Briner, M. and Salmen, A. and Engelhardt, B. and Huwiler, A. and Chan, A. and Hoepner, R.",
    journal = "CNS Neuroscience and Therapeutics",
    year = "2018",
    volume = "24",
    number = "10",
    pages = "984-986",
    publisher = "Wiley-Blackwell Publishing Ltd",
    doi = "10.1111/cns.12992",
    keywords = "cyclophosphamide;  fingolimod;  fumaric acid dimethyl ester;  gadolinium;  glatiramer;  liver enzyme;  natalizumab;  rituximab;  fingolimod;  immunosuppressive agent, adult;  adverse outcome;  brain disease;  clinical article;  cohort analysis;  disease course;  disease severity;  drug half life;  drug withdrawal;  epidemiology;  fatigue;  female;  human;  Letter;  lymphocytopenia;  male;  middle aged;  morbidity;  motor dysfunction;  multiple sclerosis;  neoplasm;  neuroimaging;  nuclear magnetic resonance imaging;  patient preference;  phenotype;  recurrent disease;  retrospective study;  risk assessment;  risk factor;  sensory dysfunction;  Switzerland;  treatment withdrawal;  university hospital;  unspecified side effect;  multiple sclerosis;  recurrent disease;  withdrawal syndrome, Adult;  Female;  Fingolimod Hydrochloride;  Humans;  Immunosuppressive Agents;  Male;  Middle Aged;  Multiple Sclerosis;  Recurrence;  Retrospective Studies;  Substance Withdrawal Syndrome"
}